Pulmonx Corp (LUNG): who owns it and who trades it
As of Nov 16, 2026, LUNG insiders reported 55 open-market sales worth $548K and no purchases in the last 12 months, with 8% of the sale value made under pre-set 10b5-1 plans. The largest seller was Glendon E. French III (CEO), with $292K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pulmonx
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LUNG
108 funds and institutions reported LUNG shares worth $34.1M at the end of Q2 2026, about 62% of the company. The largest holder is Primecap Management Co with 10.9%.
Funds and institutions (13F) 62%Everyone else 38%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Primecap Management Co | 4.61M | 10.92% | $6M | -2% |
| Morgan Stanley | 2.92M | 6.92% | $3.8M | -27% |
| Soleus Capital Management, L.P. | 2.79M | 6.60% | $3.6M | No change |
| Vanguard Capital Management LLC | 1.63M | 3.86% | $2.1M | -0% |
| ExodusPoint Capital Management, LP | 1.22M | 2.90% | $1.6M | -37% |
| Almitas Capital LLC | 1.06M | 2.52% | $1.4M | – |
| BlackRock, Inc. | 882,490 | 2.09% | $1.1M | -67% |
| Stonepine Capital Management, LLC | 815,436 | 1.93% | $1.1M | +6% |
| Jane Street Group, LLC | 758,231 | 1.80% | $986K | +469% |
| Braidwell LP | 752,541 | 1.78% | $978K | No change |
| AQR Capital Management LLC | 744,963 | 1.76% | $968K | +108% |
| Parkman Healthcare Partners LLC | 646,564 | 1.53% | $841K | -14% |
| Geode Capital Management, LLC | 452,684 | 1.07% | $589K | -52% |
| Renaissance Technologies LLC | 425,110 | 1.01% | $553K | +33% |
| ADAR1 Capital Management, LLC | 404,497 | 0.96% | $526K | +8% |
| Deutsche Bank Ag\ | 402,316 | 0.95% | $523K | -65% |
| D. E. Shaw & Co., Inc. | 327,528 | 0.78% | $426K | -2% |
| Jefferies Financial Group Inc. | 285,110 | 0.68% | $371K | No change |
| Cfm Wealth Partners LLC | 264,039 | 0.63% | $343K | No change |
| Vanguard Fiduciary Trust Co | 250,511 | 0.59% | $326K | -11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LUNG insiders reported $0 of open-market purchases and $548K of sales. 8% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Glendon E. French III | CEO | Sale | 4,098 | $2.26 | $9.3K | Form 4 |
| Sep 1, 2026 | Glendon E. French III | CEO | Sale | 37,784 | $2.26 | $85.4K | Form 4 |
| Sep 1, 2026 | Srikanth Radhakrishnan | Chief Science & Techn. O | Sale | 2,643 | $2.26 | $6K | Form 4 |
| Sep 1, 2026 | Srikanth Radhakrishnan | Chief Science & Techn. O | Sale | 5,863 | $2.26 | $13.3K | Form 4 |
| Sep 1, 2026 | Srikanth Radhakrishnan | Chief Science & Techn. O | Sale | 3,618 | $2.26 | $8.2K | Form 4 |
| Sep 1, 2026 | Srikanth Radhakrishnan | Chief Science & Techn. O | Sale | 2,121 | $2.26 | $4.8K | Form 4 |
| Sep 1, 2026 | David Aaron Lehman | General Counsel | Sale | 3,807 | $2.26 | $8.6K | Form 4 |
| Sep 1, 2026 | David Aaron Lehman | General Counsel | Sale | 4,827 | $2.26 | $10.9K | Form 4 |
| Sep 1, 2026 | David Aaron Lehman | General Counsel | Sale | 3,476 | $2.26 | $7.9K | Form 4 |
| Sep 1, 2026 | David Aaron Lehman | General Counsel | Sale | 2,224 | $2.26 | $5K | Form 4 |
| Sep 1, 2026 | Geoffrey Beran Rose | Chief Commercial Officer | Sale | 2,213 | $2.26 | $5K | Form 4 |
| Sep 1, 2026 | Geoffrey Beran Rose | Chief Commercial Officer | Sale | 1,530 | $2.26 | $3.5K | Form 4 |
| Sep 1, 2026 | Geoffrey Beran Rose | Chief Commercial Officer | Sale | 1,746 | $2.26 | $3.9K | Form 4 |
| Sep 1, 2026 | Geoffrey Beran Rose | Chief Commercial Officer | Sale | 2,390 | $2.26 | $5.4K | Form 4 |
| Jun 2, 2026 | Glendon E. French III | CEO | Sale | 13,511 | $1.57 | $21.2K | Form 4 |
| Jun 1, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 3,684 | $1.54 | $5.7K | Form 4 |
| Jun 1, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 5,969 | $1.54 | $9.2K | Form 4 |
| Jun 1, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 2,691 | $1.54 | $4.1K | Form 4 |
| Jun 1, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 2,153 | $1.54 | $3.3K | Form 4 |
| Jun 1, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 3,539 | $1.54 | $5.5K | Form 4 |
| Jun 1, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 4,915 | $1.54 | $7.6K | Form 4 |
| Jun 1, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 3,876 | $1.54 | $6K | Form 4 |
| Jun 1, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 2,264 | $1.54 | $3.5K | Form 4 |
| Jun 1, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 1,557 | $1.54 | $2.4K | Form 4 |
| Jun 1, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 1,778 | $1.54 | $2.7K | Form 4 |
| Jun 1, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 2,254 | $1.54 | $3.5K | Form 4 |
| Jun 1, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 2,434 | $1.54 | $3.7K | Form 4 |
| Jun 1, 2026 | Glendon E. French III | CEO | Sale | 4,171 | $1.54 | $6.4K | Form 4 |
| Jun 1, 2026 | Glendon E. French III | CEO | Sale | 38,467 | $1.54 | $59.2K | Form 4 |
| Mar 2, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 4,198 | $1.43 | $6K | Form 4 |
| Mar 2, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 2,461 | $1.43 | $3.5K | Form 4 |
| Mar 2, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 756 | $1.43 | $1.1K | Form 4 |
| Mar 2, 2026 | Srikanth Radhakrishnan | Chief Science &Techn. Of | Sale | 3,068 | $1.43 | $4.4K | Form 4 |
| Mar 2, 2026 | Glendon E. French III | CEO | Sale | 58,368 | $1.43 | $83.5K | Form 4 |
| Mar 2, 2026 | Glendon E. French III | CEO | Sale | 2,708 | $1.43 | $3.9K | Form 4 |
| Mar 2, 2026 | Glendon E. French III | CEO | Sale | 6,737 | $1.43 | $9.6K | Form 4 |
| Mar 2, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 2,911 | $1.43 | $4.2K | Form 4 |
| Mar 2, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 2,125 | $1.43 | $3K | Form 4 |
| Mar 2, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 835 | $1.43 | $1.2K | Form 4 |
| Mar 2, 2026 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 1,861 | $1.43 | $2.7K | Form 4 |
| Mar 2, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 1,163 | $1.43 | $1.7K | Form 4 |
| Mar 2, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 4,433 | $1.43 | $6.3K | Form 4 |
| Mar 2, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 4,051 | $1.43 | $5.8K | Form 4 |
| Mar 2, 2026 | David Aaron Lehman | GENERAL COUNSEL | Sale | 2,590 | $1.43 | $3.7K | Form 4 |
| Dec 8, 2025 | Daniel P Florin | Director | Sale plan | 23,321 | $1.99 | $46.4K | Form 4 |
| Dec 1, 2025 | Glendon E. French III | CEO | Sale | 2,524 | $1.57 | $4K | Form 4 |
| Dec 1, 2025 | Glendon E. French III | CEO | Sale | 6,281 | $1.57 | $9.9K | Form 4 |
| Dec 1, 2025 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 1,522 | $1.57 | $2.4K | Form 4 |
| Dec 1, 2025 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 1,738 | $1.57 | $2.7K | Form 4 |
| Dec 1, 2025 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 683 | $1.57 | $1.1K | Form 4 |
| Dec 1, 2025 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sale | 2,379 | $1.57 | $3.7K | Form 4 |
| Dec 1, 2025 | David Aaron Lehman | GENERAL COUNSEL | Sale | 2,176 | $1.57 | $3.4K | Form 4 |
| Dec 1, 2025 | David Aaron Lehman | GENERAL COUNSEL | Sale | 3,725 | $1.57 | $5.8K | Form 4 |
| Dec 1, 2025 | David Aaron Lehman | GENERAL COUNSEL | Sale | 976 | $1.57 | $1.5K | Form 4 |
| Dec 1, 2025 | David Aaron Lehman | GENERAL COUNSEL | Sale | 3,401 | $1.57 | $5.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Glendon E. French III | President and CEO, Director | – | $292K | Sep 1, 2026 |
| David Aaron Lehman | GENERAL COUNSEL | – | $88.5K | Sep 1, 2026 |
| Srikanth Radhakrishnan | Chief Science &Techn. Officer | – | $69.5K | Sep 1, 2026 |
| Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | – | $51.1K | Sep 1, 2026 |
| Daniel P Florin | Director | – | $46.4K | Dec 8, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LUNG short interest
Low short interest. 1.8% of LUNG shares are sold short: about 1 share in 55. Over the last 12 reports the number of shares short went down 71%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 787,512 LUNG shares were sold short, 1.8% of the shares outstanding, up 12.7% from the report before. At the average daily volume of 1.60M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 787,512 | 1.81% | +13% | 1.60M | 1.0 |
| Oct 15, 2026 | 698,644 | 1.63% | -13% | 274,705 | 2.5 |
| Sep 30, 2026 | 802,733 | 1.87% | -5% | 251,008 | 3.2 |
| Sep 15, 2026 | 847,842 | 1.97% | -13% | 337,301 | 2.5 |
| Aug 31, 2026 | 976,237 | 2.27% | -8% | 377,844 | 2.6 |
| Aug 14, 2026 | 1.07M | 2.48% | +1% | 900,647 | 1.2 |
| Jul 31, 2026 | 1.06M | 2.47% | +0% | 730,617 | 1.4 |
| Jul 15, 2026 | 1.06M | 2.50% | -8% | 227,542 | 4.6 |
| Jun 30, 2026 | 1.15M | 2.72% | -49% | 862,593 | 1.3 |
| Jun 15, 2026 | 2.26M | 5.36% | -20% | 314,151 | 7.2 |
| May 29, 2026 | 2.82M | 6.67% | +4% | 417,128 | 6.8 |
| May 15, 2026 | 2.70M | 6.39% | -24% | 567,004 | 4.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Pulmonx company events
Pulmonx filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.
- Oct 27, 2026ResultsReleased financial results. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Mar 5, 2026AgreementPulmonx Corporation entered into a Credit Agreement and Guaranty and a Security Agreement, with Perceptive Credit Holdings V, LP, as the initial lender, administrative agent and collateral agent. Filing
- Mar 4, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Pulmonx financials
Famous investors that hold LUNG
4 of the 50 well-known investors we track reported holding LUNG in their latest 13F filing. The largest position is Jim Simons's, worth $1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 530,336 | $1M | 0.0% | +25% |
| Israel Englander · Millennium Management | Q3 2026 | 179,957 | $344K | 0.0% | -14% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 61,120 | $117K | 0.0% | -57% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 10,067 | $19.2K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LUNG in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | PRIMECAP MANAGEMENT CO/CA/ | 13G/A | 10.3% |
| Nov 5, 2026 | PRIMECAP MANAGEMENT CO/CA/ | 13G/A | 10.3% |
Questions about Pulmonx Corp (LUNG) stock
Who owns the most LUNG stock?
The largest reported owner of Pulmonx Corp (LUNG) is Primecap Management Co, with 10.9% of the company. In total, 108 funds and institutions reported holding LUNG at the end of Q2 2026, together about 62% of the shares. See the largest owners.
Are LUNG insiders buying or selling?
In the last 12 months, LUNG insiders reported no open-market purchases and 55 sales worth $548K. The latest trade was on Sep 1, 2026. See every trade.
What is the short interest in LUNG?
As of Oct 30, 2026, 787,512 LUNG shares were sold short, 1.8% of the shares outstanding, up 12.7% from the report before. At the average daily volume of 1.60M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold LUNG?
4 of the 50 well-known investors we track reported LUNG in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.